-
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Gelissen, L. M. Y., Toorop, A. A., Schipper, P. M., Hoitsma, E., Zeinstra, E. M. P. E., van Rooij, L. C., van Munster, C. E. P., Vennegoor, A., Mostert, J., Wokke, B., Kalkers, N. F., Hoogervorst, E. L. J., van Eijk, J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L. G. F. & Kloosterziel, M. E. & 11 others, , 1 Nov 2025, In: Journal of neurology, neurosurgery, and psychiatry. 96, 11, p. 1038-1045 8 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)
Fung, W. H., Wessels, M. H. J., Coerver, E. M. E., de Beukelaar, J., Bouvy, W. H., Canta, L. R., Gerlach, O. H. H., Hoitsma, E., Hoogervorst, E. L. J., de Jong, B. A., Kalkers, N. F., van Kempen, Z. L. E., Lövenich, H., van Munster, C. E. P., van Oosten, B. W., Smolders, J., Vennegoor, A., Zeinstra, E. M. P. E., Barrantes-Cepas, M. & Kooij, G. & 9 others, , Aug 2025, In: Journal of Neurology. 272, 8, 530.Research output: Contribution to journal › Article › Academic › peer-review
-
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial
Coerver, E. M. E., Fung, W. H., de Beukelaar, J., Bouvy, W. H., Canta, L. R., Gerlach, O. H. H., Hoitsma, E., Hoogervorst, E. L. J., de Jong, B. A., Kalkers, N. F., van Kempen, Z. L. E., Lövenich, H., van Munster, C. E. P., van Oosten, B. W., Smolders, J., Vennegoor, A., Zeinstra, E. M. P. E., Barrantes-Cepas, M., Kooij, G. & Schoonheim, M. M. & 8 others, , 9 Dec 2024, (E-pub ahead of print) In: JAMA Neurology.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
